-

$undefined

N/A

(N/A)

Jazz Pharmaceuticals NASDAQ:JAZZ Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.

Location: Waterloo Exchange, Waterloo Road,Dublin 4, Ireland | Website: www.jazzpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

10.8B

Cash

1.981B

Avg Qtr Burn

N/A

Short % of Float

5.63%

Insider Ownership

2.88%

Institutional Own.

97.07%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EPIDIOLEX® (cannabidiol) Details Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zepzelca (Lurbinectedin) Details Cancer, Small cell lung cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rylaze /Enrylaze (JZP-458) Details Acute lymphoblastic leukemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Xywav (JZP-258) (oxybate salts) Details EDS in Idiopathic Hypersomnia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab Details HER2-expressing cancers, Cancer, Biliary Tract Cancer	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab + chemo / trastuzumab +chemotherapy Details Cancer, Breast cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPIDIOLEX® (cannabidiol) Details Rare diseases, Neurological disorder, Rare genetic disease, Epilepsy, Seizures	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab combo w/ chemo Details Cancer, HER2-expressing cancers, Gastroesophageal adenocarcinomas	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zepzelca +Tecentriq Details Cancer, Small cell lung cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Suvecaltamide (JZP-385) Details Essential tremor	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zepzelca (Lurbinectedin) Details Cancer, Solid tumor/s	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Suvecaltamide (JZP-385) Details Parkinson's disease	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CBDV (Cannabidivarin /GWP42006) Details Epilepsy, Autism spectrum disorders	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab + Palbociclib + Fulvestrant Details Cancer, ER+/HER2- breast cancer	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zepzelca (Lurbinectedin) Details Solid tumor/s, Cancer, Endometrial cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zepzelca (Lurbinectedin) w/ ipilimumab and nivolumab Details Cancer, Soft tissue sarcoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab combo w/ docetaxel Details Cancer, HER2-expressing cancers	Phase 1/2 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JZP351 (CPX-351) Details Acute myeloid leukemia, Blood cancer, Cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zanidatamab Details Cancer, Breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JZP815 Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JZP441 (orexin-2 receptor agonist) Details Sleeping disorder, EDS in Idiopathic Hypersomnia , Narcolepsy	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JZP898 Details Solid tumor/s, Cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
JZP-150 (FAAH inhibitor) Details Post-traumatic stress disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EPIDIOLEX® (cannabidiol) Details Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nabiximols Details Multiple sclerosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.